# Maxcyte (MXCT) — Analyst Forecast

MXCT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mxct/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 5 | 1 | 0 | 6 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Mar 25, 2026 | Craig-Hallum | Maintained | Buy | $5.00 |
| Aug 11, 2025 | BTIG | Downgraded | Buy → Neutral | — |
| Aug 7, 2025 | William Blair | Downgraded | Outperform → Market Perform | — |
| Jul 22, 2025 | Stephens & Co. | Initiated Coverage | Overweight | $6.00 |
| Mar 12, 2025 | Stifel | Maintained | Buy | $9.00 |
| Apr 23, 2024 | Stephens & Co. | Maintained | Overweight | $11.00 |
| Mar 13, 2024 | BTIG | Maintained | Buy | $8.00 |
| Mar 13, 2024 | Stephens & Co. | Maintained | Overweight | $11.00 |
| Nov 29, 2023 | Craig-Hallum | Initiated Coverage | Buy | $7.00 |
| Oct 5, 2023 | Stephens & Co. | Maintained | Overweight | $12.00 |

## Frequently Asked Questions

### Is MXCT a buy, sell, or hold?

Analysts covering Maxcyte currently average a Buy rating: 5 buy, 1 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on MXCT?

On Mar 25, 2026, Craig-Hallum maintained Maxcyte at Buy with a price target of $5.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).